Adial Pharmaceuticals has announced the issuance of patent number 12,226,401, which enhances their genetic-based approach for treating alcohol and opioid use disorders. This new patent focuses on ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 7.1% of patients with AUD and cirrhosis in the naltrexone group vs. 28.6% in the placebo group had ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...